Glioblastoma multiforme (GBM) is the most common malignant brain tumor in adults and remains one of the most difficult cancers to treat. Characterized by aggressive growth and diffuse microscopic spread, GBM infiltrates surrounding brain tissue beyond what can be seen on imaging or during surgery. As a result, recurrence is common, and long-term survival rates have changed little despite decades of research.
Standard care for GBM typically involves surgical removal of the visible tumor, followed by radiation therapy and chemotherapy. Patients often present with symptoms such as persistent headaches, seizures, nausea, or impairments in movement and speech, with diagnosis confirmed through MRI imaging. While surgery can address the main tumor mass, residual cancer cells embedded within apparently healthy brain tissue pose a major therapeutic challenge.
As reported on Forbes, a novel investigational approach aims to overcome this limitation by targeting these hard-to-detect cancer cells. In a recently completed Phase 1 clinical trial published in Neuro-Oncology in 2024, researchers tested a treatment combining the oral drug 5-aminolevulinic acid (5‑ALA) with low-intensity ultrasound. The therapy is designed to sensitize tumor-infiltrated brain tissue to ultrasound energy, allowing widespread treatment of the affected brain hemisphere without damaging normal structures.
In the Phase 1 study, the therapy was administered to patients whose GBM had returned after standard treatment. Participants took 5‑ALA prior to receiving diffuse ultrasound delivered across the half of the brain containing residual disease. Investigators reported a median survival extension of more than one year compared with expected outcomes for recurrent GBM—an important finding given that overall survival for this disease remains poor, with fewer than half of patients living one year after diagnosis and only a small minority surviving beyond five years.
Building on these results, the Glioblastoma Brain Cancer Trial has now progressed to Phase 2. This stage includes patients newly diagnosed with GBM, many of whom are undergoing conventional treatments alongside the experimental protocol. The goal is to evaluate whether combining 5‑ALA and ultrasound earlier in the disease course can reduce the burden of microscopic tumor cells present both at diagnosis and after initial surgery, radiation, and chemotherapy.
The trial is supported by Alpheus Medical, a biotechnology company focused on noninvasive therapies for brain disease. The company is led by Dr. Vijay Agarwal, Associate Professor of Neurosurgery and Otolaryngology and Director of the Brain Tumor Center at Albert Einstein College of Medicine. Dr. Agarwal, who has practiced neurosurgery for nearly 20 years, has emphasized the need for innovative strategies that reflect the diffuse nature of GBM. He notes that meaningful advances in brain cancer treatment have been rare, highlighting the urgency for new approaches.
To date, the Phase 2 trial has not reported significant treatment-related safety concerns. Early observations suggest patients may be living longer than expected with standard therapy alone, with some experiencing stabilization or slowing of tumor progression. While further follow-up is required to determine long-term benefit, researchers are encouraged by the initial outcomes.
If ongoing studies continue to demonstrate safety and efficacy, this ultrasound-based strategy could represent a meaningful step forward in addressing one of the most lethal and treatment-resistant cancers in medicine.
